Introduction
5-Fluorouracil (5-FU) has been widely used to treat patients with various cancers, such as gastrointestinal, head and neck, and breast cancer, for more than four decades, and its effi cacy has been improved by various clinical approaches such as changes of dosing schedules from bolus injection to continuous infusion and the addition of leucovorin (LV). Also, oral formulations of 5-FU as 5-FU prodrugs have been developed to obtain convenient and long-term use in cancer patients. Although 5-FU and its prodrugs are currently administered in combination with other cytotoxic drugs to prolong the survival time of cancer patients, there are unresolved problems with the metabolism of 5-FU and unacceptable toxicities induced by 5-FU, such as gastrointestinal (GI) damage.
5-FU is mainly converted to 5-fl uoro-uridine-5′-monophosphate by orotate phosphoribosyltransferase (OPRT) and is further metabolized to 5-fl uoro-2′-deoxyuridine 5′-monophosphate (FdUMP), which tightly binds to thymidylate synthase (TS), a key enzyme in DNA synthesis, with methylene-tetrahydrofolate in tumor, bone marrow, and GI tissues to exert its antitumor activity and toxic effect. However, the majority of 5-FU (about 80%) is known to be catabolized to an inactive form by dihydropyrimidine dehydrogenase (DPD) in the liver and tumor tissues. Both strong inhibition of DPD and protection against GI toxicity are therefore needed to potentiate the effi cacy of 5-FU without incurring 5-FU-induced severe GI toxicity.
We attempted to develop a novel oral 5-FU formulation which could resolve clinical problems such as those described above. In this review, the characteristics and activities of S-1 alone and in combination with other antitumor drugs used for GI cancer treatment are described.
Preclinical characteristics of S-1
S-1 is a new oral formulation of 5-FU consisting of 1 M tegafur, 0.4 M 5-chloro-2, 4-dihydroxypyridine (CDHP; gimeracil), and 1 M potassium oxonate (Oxo; potassium oteracil) [1] . The development of S-1 for notable efficacy and lower toxicity in cancer patients was based on the strong inhibition of DPD, leading to high and persistent 5-FU levels in blood and tumors, and the regulation of OPRT in the GI tract, which led to a decrease in GI toxicity, and CDHP [2] and Oxo [3] , found by us, enabled the establishment of a new oral 5-FU formulation. When compared with 5-FU infusion, S-1 showed higher antitumor effi cacy and lower toxicity in a rodent tumor model, judged by a decrease in the weight of rats, as shown in Fig. 1 [4] , suggesting that oral S-1 could contribute to the treatment of cancer patients with higher effi cacy and lower GI toxicity compared with infusional 5-FU. The antitumor potency of S-1 also seemed to be greater than that of other oral 5-FU prodrugs in various human cancer xenografts subcutaneously implanted into rodents [5] . Konno et al. [6] and we, independently, evaluated the therapeutic effect of S-1 on human colon carcinoma orthotopically implanted into mice and rats, and found that S-1 signifi cantly inhibited the growth of primary tumors and the metastasis of those tumors to liver [6] or lung [7] , suggesting the possibility of clinical benefi t to cancer patients.
Combination of S-1 with cisplatin
Cisplatin (CDDP) is currently most available therapeutic drug to treat patients with gastric, head and neck, and non-small cell lung cancers. Therefore, the combined effect of oral S-1 with CDDP was investigated against rodent and human GI tumors. Kondo and colleagues [8] reported the antitumor activity of daily S-1 combined with high-dose weekly and lower-dose daily CDDP on NUGC-4 tumors in nude mice. We examined whether S-1 plus CDDP achieved the most prolonged survival compared to the combination of S-1 with other anticancer drugs, such as mitomycin-C, irinotecan, and adriamycin in colon 26 PMF-15-bearing mice. As shown in Table 1 , S-1 plus CDDP was the most effective combination in prolonging survival in the tumor-bearing mice (unpublished data). These preclinical results suggest that S-1 plus CDDP would be a useful regimen for the treatment of patients with advanced and metastatic gastric cancer.
Two hypotheses for the mechanism of the synergistic anticancer effect exerted by fl uoropyrimidine plus CDDP have been advanced, by Shirasaka et al. [9] and Nakano and Niho [10] . One mechanism is an increase in intercellular reduced folate levels induced by CDDP, which potentiates the formation of ternary complex by TS, methylenetetrahydrofolate, and FdUMP derived from 5-FU, and the other mechanism is the cooperative reinforcement of DNA damage in the tumor by 5-FU followed by CDDP.
Combination of S-1 with irinotecan
Recently, in a number of basic and clinical studies, the expression levels of tumoral TS have been suggested to limit the antitumor effi cacy of 5-FU, and we have also confi rmed that S-1 showed less antitumor effi cacy against human GI cancer xenografts with innate and acquired resistance to 5-FU in which TS was highly expressed [11] . Therefore, the combination of S-1 with other anticancer drugs possessing the ability to downregulate highly expressed tumoral TS may be considered to be useful for the treatment of GI cancer patients. Takiuchi and colleagues [12] reported that irinotecan (which is used clinically to treat gastric and colorectal cancer patients) reduced highly expressed TS in human gastric cancer 4-1-ST and AZ-521, but not SC-2 xenografts, and showed synergistic antitumor activity in combination with S-1 in the 4-1-ST and AZ-521, tumors, while irinotecan plus S-1 therapy was not effective against SC-2 tumors compared with irinotecan and S-1 alone (Table 2 ; Fig. 2 ). We further evaluated the antitumor effects of the combination of irinotecan with S-1 against parental and 5-FU-resistant colon cancer KM12C xenografts in mice [13] . As shown in Fig. 3 , irinotecan plus S-1 signifi cantly (P < 0.01) affected KM12C/5-FU tumors in which S-1 alone showed less antitumor activity, and the activity of irinotecan plus S-1 was similar to that in the parental KM12C tumors. When irinotecan was i.v. administered, the highly expressed TS levels were signifi cantly decreased in KM12C/5-FU tumors, but not in parental KM12C tumors showing low TS activity. In regard to the molecular mechanism of the downregulation of TS by irinotecan in gastric and colon tumors with highly expressed levels of TS, it is suggested that cell cycle-regulating proteins, including CDK4 in the G1 phase of the cell, are regulated by the inhibition of topoisomerase followed by a decrease in p-RB and E2F1 proteins, which possibly downregulate the highly expressed levels of TS in the S phase of the cells (Fig. 4) . These results reveal that combined therapy with S-1 and irinotecan could be especially useful for the treatment of GI cancer patients with originally high and/or elevated levels of TS. *,** Signifi cantly different from nontreated (control) group (P < 0.05 and P < 0.01, respectively) by Dunnett's test CPT-11 (75 mg/kg) was administered i.v. weekly, twice, to nude mice (n = 5) bearing human gastric cancer xenografts, and 24 h later, tumors were removed and their activities of 5-FU-metabolizing enzymes were measured Control tumor group received only saline TS, thymidylate synthase; DPD, dihydropyrimidine dehydrogenase; OPRT, orotate phosphoribosyltransferase; TP, thymidine phosphorylase; RNR, ribonucleotide reductase; TK, thymidine kinase 
Combination of S-1 with taxanes
A combination of S-1 with taxanes is thought to be a feasible regimen to treat gastric cancer patients if the taxane biochemically modulates the metabolism or function of 5-FU. For this, Wada et al. [14] investigated the antitumor effects of docetaxel and S-1, using human gastric cancer TMK cells in vitro and in vivo, and they demonstrated that the synergistic antitumor effects of S-1 and docetaxel (as seen in Fig. 5 ) were based on the modulation of 5-FU-metabolizing enzymes. The expression of TS and DPD signifi cantly decreased and that of OPRT notably increased in docetaxel-treated TMK-1 cells in vitro. In the in vivo tumor models, it is, however, uncertain whether the administration of docetaxel possibly induces a decrease in TS and DPD and an increase in OPRT in TMK-1 tumors. We verifi ed the effect of docetaxel on the activities of 5-FU-metabolizing enzymes in both parental and 5-FU-treated gastric cancer NUGC-3 xenografts in vivo. Weekly administration of docetaxel signifi cantly reduced the activity of TS in the 5-FU-treated tumors, but not in the parental tumors ( Table 3 ), suggesting that combined administration of docetaxel with S-1 could overcome the tumor cell resistance to 5-FU in gastric cancer xenografts with acquired resistance to 5-FU. As seen in Fig. 6 , S-1 plus docetaxel showed signifi cantly higher antitumor activity compared to S-1 alone (which showed no antitumor effect) and compared to docetaxel alone against NUGC-3/5-FU tumor xenografts. The combination of S-1 with Throughout these experiments, it appeared that S-1 plus docetaxel could contribute to the treatment of gastric cancer patients in whom S-1 monotherapy or S-1-based combination therapy had failed.
Discussion
At present, among 5-FU and its oral prodrugs, S-1, as a DPD-inhibitory fl uoropyrimidine (DIF), is thought to be the most effective to treat patients with GI cancer. Throughout our preclinical experiments with S-1 alone and/or in combination with CDDP, irinotecan, or docetaxel, these combination therapies showed potential antitumor effi cacy against human GI tumor xenografts. Especially, S-1 plus irinotecan and S-1 plus docetaxel showed synergistic antitumor activity in 5-FU-resistant GI cancer xenografts with highly elevated levels of TS expression, fi ndings which suggest that alternating or sequential treatment with the three regimens; S-1/CDDP, S-1/irinotecan, and S-1/docetaxel, could prolong survival in cancer patients.
Recently, various molecular targeted agents, including humanized monoclonal antibodies and receptor tyrosine kinase inhibitors, have been developed and introduced to treat GI cancer patients. These drugs exhibit an antitumor effect when combined with classical cytotoxic drugs, and therefore, combinations of S-1-containing regimens with molecular targeted agents would be interesting subjects to further improve the survival of patients with GI cancer. 
